“Given that this treatment is also likely to be much less toxic than most cancer therapies for these types of tumors, in addition to showing remarkable therapeutic effects against aggressive disease, we think these results warrant further exploration of the agent in clinical trials.” “The results of our studies show that the cancer therapeutic we developed is highly effective in treating at least three different types of high-risk pediatric solid tumors with intrinsic or acquired drug resistance,” explained co-senior study investigator Garrett Brodeur, MD, director of the Cancer Predisposition Program at CHOP. Findings from the new study were published recently in Cancer Research through an article titled, “ Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.” Now, a team of investigators at the Children’s Hospital of Philadelphia (CHOP) has just released new data describing an enhanced treatment that leads to long-term remissions in 80–100% of mice with drug-resistant or high-risk solid tumors. As such, scientists and clinicians are always on the hunt for new drugs or new ways to deliver old drugs to make them more efficacious to patients. Chemotherapy given orally or intravenously generally does not deliver enough of the drug to the tumor, which not only renders the chemotherapeutic agent ineffective but also leads to increased drug resistance-combined with the all too common and almost unavoidable side effects such as severe diarrhea, bone marrow suppression, and secondary malignancies. Solid tumors are notoriously difficult to treat and often put children into a high-risk category as tumors like neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma in these patients often don’t respond to conventional therapies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |